CRISPR-Cas9 approach identifies new drug targets to aid cancer immunotherapy
A novel CRISPR-Cas9 screening method developed by a team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center (Boston, MA, USA) has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapeutics.
Please sign in or register for FREE to view this content
Sign in to MedChemNet
Register to MedChemNet – the medicinal chemistry network
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.